An agreement between UCLA and Roche will provide stem-cell and cancer researchers with technologies that will drive research capabilities and further the understanding of complex diseases.
The technologies, including the latest-generation microarray systems from Roche Nimblegen, high-throughput screening instruments, genetic-expression profilers and exome-sequencing technologies, will provide scientists with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and UCLA's Jonsson Comprehensive Cancer Center with technology directly from Roche's research and development pipeline.
Under the agreement, Roche will also provide UCLA with advanced reagent, technologies and bioinformatics support to be used in the pursuit of discovering new predictive biomarkers, which will be used as targets for future therapeutics and diagnostics for a host of diseases.
The agreement opens the door for UCLA and Roche scientists to work collaboratively with an initial focus on developing even more effective technologies for academic and commercial use.
Future developments, based on these technologies, could lead to clinical trials of promising diagnostics and therapeutics.
Michael Teitell said that UCLA researchers will submit project applications for research using the new technology and an advisory committee comprised of Roche and UCLA scientists will review and select the projects that propose the best use of the technology and that are most likely to succeed.
